Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$23.38 USD
+0.25 (1.08%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $23.38 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About Return on Equity (TTM)
Apellis Pharmaceuticals, Inc.'s return on equity, or ROE, is -116.09% compared to the ROE of the Medical - Biomedical and Genetics industry of -67.20%. While this shows that APLS has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
APLS 23.38 +0.25(1.08%)
Will APLS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLS
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say
Repligen (RGEN) Lags Q2 Earnings Estimates
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
Other News for APLS
50 Day Moving Average Resistance appears for APLS after 2.9% move
Fell Below 50 Day Moving Average appears for APLS after 2.34% move
Is APLS ready to move higher? 50 Day Moving Average Support shows up after sliding 1.85%
APLS Crosses Below Key Moving Average Level
NR7 appears for APLS after 2.17% move